Compare Dishman Pharma with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SANOFI INDIA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SANOFI INDIA DISHMAN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 25.1 43.0 58.3% View Chart
P/BV x 3.3 8.8 38.2% View Chart
Dividend Yield % 0.7 1.0 66.8%  

Financials

 DISHMAN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SANOFI INDIA
Dec-18
DISHMAN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3746,840 5.5%   
Low Rs1294,630 2.8%   
Sales per share (Unadj.) Rs197.81,203.1 16.4%  
Earnings per share (Unadj.) Rs21.2165.3 12.8%  
Cash flow per share (Unadj.) Rs34.7209.9 16.5%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.81.5 54.3%  
Book value per share (Unadj.) Rs179.9963.6 18.7%  
Shares outstanding (eoy) m80.6923.03 350.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.8 26.7%   
Avg P/E ratio x11.934.7 34.2%  
P/CF ratio (eoy) x7.227.3 26.5%  
Price / Book Value ratio x1.46.0 23.5%  
Dividend payout %9.450.8 18.6%   
Avg Mkt Cap Rs m20,306132,078 15.4%   
No. of employees `0000.83.3 25.1%   
Total wages/salary Rs m5,3554,068 131.6%   
Avg. sales/employee Rs Th19,252.78,393.8 229.4%   
Avg. wages/employee Rs Th6,459.51,232.4 524.2%   
Avg. net profit/employee Rs Th2,064.11,153.0 179.0%   
INCOME DATA
Net Sales Rs m15,96127,708 57.6%  
Other income Rs m265897 29.6%   
Total revenues Rs m16,22628,605 56.7%   
Gross profit Rs m4,1036,235 65.8%  
Depreciation Rs m1,0911,027 106.2%   
Interest Rs m9447 13,491.4%   
Profit before tax Rs m2,3346,098 38.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,292 27.2%   
Profit after tax Rs m1,7113,806 45.0%  
Gross profit margin %25.722.5 114.2%  
Effective tax rate %26.737.6 71.1%   
Net profit margin %10.713.7 78.0%  
BALANCE SHEET DATA
Current assets Rs m11,01815,922 69.2%   
Current liabilities Rs m9,5176,235 152.6%   
Net working cap to sales %9.435.0 26.9%  
Current ratio x1.22.6 45.3%  
Inventory Days Days11064 173.6%  
Debtors Days Days3521 167.0%  
Net fixed assets Rs m16,3047,539 216.3%   
Share capital Rs m161230 70.2%   
"Free" reserves Rs m12,90721,962 58.8%   
Net worth Rs m14,51622,192 65.4%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80529,839 99.9%  
Interest coverage x3.5872.1 0.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.9 57.7%   
Return on assets %8.912.8 69.7%  
Return on equity %11.817.2 68.7%  
Return on capital %17.527.5 63.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9527,587 65.3%   
Fx outflow Rs m6977,145 9.8%   
Net fx Rs m4,255442 962.6%   
CASH FLOW
From Operations Rs m2,7863,739 74.5%  
From Investments Rs m-1,529-731 209.2%  
From Financial Activity Rs m-941-1,972 47.7%  
Net Cashflow Rs m3161,036 30.5%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 3.7 14.4 25.7%  
FIIs % 12.7 14.6 87.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 15,184 304.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ELDER PHARMA  FDC  NEULAND LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indigo Paints IPO, India's Crude Oil Production in December, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed a sharp sell-off during closing hours yesterday and ended lower.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS